Skip to main content Skip to main navigation menu Skip to site footer

Association between cartilage biomarker level and functional outcome in knee osteoarthritis patients receiving dextrose prolotherapy: a cross-sectional study

  • Yose Waluyo ,
  • Agussalim Bukhari ,
  • Endy Adnan ,
  • Sari Rajwani Artika ,
  • Ahmad Yasin ,
  • Insani Nanda Wahyuni ,
  • Budu ,


Background: Knee osteoarthritis (KOA) is a degenerative joint disease with relatively high prevalence globally and is one of the leading causes of disability in the elderly population. Dextrose prolotherapy (DPT) has been proven effective in improving functional outcomes in knee osteoarthritis. The effect of hypertonic dextrose on cartilage biomarkers has not been evaluated.

Purpose: To evaluate the association between a cartilage biomarker and changes in clinical outcomes among patients with KOA who received dextrose prolotherapy (DPT).

Patients and methods: This study was conducted with a cross-sectional design. Twenty-six participants received DPT at weeks 1, 5, and 9. Our primary measures were urinary c-terminal telopeptides of type II collagen (uCTX-II), measured by an enzyme-linked immunosorbent assay (ELISA), and the WOMAC score, measured at baseline and week 12.

Results: There were significant improvements in all WOMAC subscales and uCTX-II levels after DPT. There is no significant correlation between biomarker levels with the WOMAC score as a functional outcome indicator in KOA after DPT (p > 0.05), but there are positive correlations between pain, functional, total WOMAC score, and uCTX-II.

Conclusion: DPT may reduce cartilage degradation and improve functional outcomes in osteoarthritic knees. Significant drops in uCTX-II levels can affect functional outcomes, especially pain, functional and total WOMAC scores.


  1. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated Projected Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation Among US Adults, 2015-2040. Arthritis Rheumatol. 2016;68(7):1582-1587. doi:10.1002/art.39692.
  2. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003;919.
  3. Indonesian Rheumatology Association. Diagnosis dan Penatalaksanaan Osteoartritis. Rekomendasi IRA untuk Diagnosis dan Penatalaksanaan Osteoartritis. 2014. p13.
  4. Bisicchia S, Bernardi G, Tudisco C. HYADD 4 versus methylprednisolone acetate in symptomatic knee osteoarthritis: a single-center single-blind prospective randomized controlled clinical study with 1-year follow-up. Clin Exp Rheumatol. 2016;34(5):857-863.
  5. Jevsevar DS, Shores PB, Mullen K, Schulte DM, Brown GA, Cummins DS. Mixed Treatment Comparisons for Nonsurgical Treatment of Knee Osteoarthritis: A Network Meta-analysis. J Am Acad Orthop Surg. 2018;26(9):325-336. doi:10.5435/JAAOS-D-17-00318.
  6. Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Zamanabadi MN, Alebouyeh MR. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging. 2018;13:73-79. Published 2018 Jan 4. doi:10.2147/CIA.S147757.
  7. Yoshii Y, Zhao C, Schmelzer JD, Low PA, An KN, Amadio PC. Effects of multiple injections of hypertonic dextrose in the rabbit carpal tunnel: a potential model of carpal tunnel syndrome development. Hand (N Y). 2014;9(1):52-57. doi:10.1007/s11552-013-9599-1.
  8. Distel LM, Best TM. Prolotherapy: A Clinical Review of Its Role in Treating Chronic Musculoskeletal Pain. PM&R [Internet]. 2011 Jun;3:S78–81. Available from:
  9. Trescot A. Everything old is new again: New developments in prolotherapy. TRAPM [Internet]. 2015;(19). p14. Available from:
  10. Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med. 2000;6(2):68-80.
  11. Topol GA, Podesta LA, Reeves KD, et al. Chondrogenic Effect of Intra-articular Hypertonic-Dextrose (Prolotherapy) in Severe Knee Osteoarthritis. PM R. 2016;8(11):1072-1082. doi:10.1016/j.pmrj.2016.03.008.
  12. Lafeber FP, van Spil WE. Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time. Osteoarthritis Cartilage. 2013;21(10):1452-1464. doi:10.1016/j.joca.2013.08.012.
  13. Lotz M, Martel-Pelletier J, Christiansen C, et al. Republished: Value of biomarkers in osteoarthritis: current status and perspectives. Postgrad Med J. 2014;90(1061):171-178. doi:10.1136/postgradmedj-2013-203726rep.
  14. Valdes AM, Meulenbelt I, Chassaing E, et al. Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis. Osteoarthritis Cartilage. 2014;22(5):683-689. doi:10.1016/j.joca.2014.02.007.
  15. Abdel GH, El TS, Moghazy A. Urinary C-terminal telopeptide of type II collagen, radiological severity, and functional assessment in knee osteoarthritis: are these related? Egypt Rheumatol Rehabil. 2016;43(2):73. DOI:10.4103/1110-161X.181879.
  16. Scarpellini M, Lurati A, Vignati G, et al. Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the "Magenta osteoarthritis study". J Orthop Traumatol. 2008;9(2):81-87. doi:10.1007/s10195-008-0007-5.
  17. Selistre LFA, Gonçalves GH, Vasilceac FA, et al. The relationship between urinary C-Telopeptide fragments of type II collagen, knee joint load, pain, and physical function in individuals with medial knee osteoarthritis. Braz J Phys Ther. 2021;25(1):62-69. doi:10.1016/j.bjpt.2020.02.002.
  18. Farpour HR, Fereydooni F. Comparative effectiveness of intra-articular prolotherapy versus periarticular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: A randomized clinical trial. Electron Physician. 2017;9(11):5663-5669. Published 2017 Nov 25. doi:10.19082/5663.
  19. Eslamian F, Amouzandeh B. Therapeutic effects of prolotherapy with intra-articular dextrose injection in patients with moderate knee osteoarthritis: a single-arm study with 6 months follow up. Ther Adv Musculoskelet Dis. 2015;7(2):35-44. doi:10.1177/1759720X14566618.
  20. Hashemi M, Jalili P, Mennati S, et al. The Effects of Prolotherapy With Hypertonic Dextrose Versus Prolozone (Intraarticular Ozone) in Patients With Knee Osteoarthritis. Anesth Pain Med. 2015;5(5):e27585. Published 2015 Oct 17. doi:10.5812/aapm.27585.
  21. Sanyal R, Goswami S, Dasgupta SR, and Basu S. Comparative study of intra articular hyaluronic acid and intra articular and para articular dextrose prolotherapy in mild to moderate knee osteoarthrosis. International Journal of Contemporary Medical Research. 2018;5(1):20-23.
  22. Arias-Vázquez PI, Tovilla-Zárate CA, Legorreta-Ramírez BG, et al. Prolotherapy for knee osteoarthritis using hypertonic dextrose vs other interventional treatments: systematic review of clinical trials. Adv Rheumatol. 2019;59(1):39. doi:10.1186/s42358-019-0083-7.
  23. Waluyo Y, Budu, Bukhari A, et al. Changes in levels of cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: A randomized controlled trial. J Rehabil Med. 2021;53(5):jrm00196. Published 2021 May 24. doi:10.2340/16501977-2835.
  24. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum. 2006;54(8):2441-2451. doi:10.1002/art.22009.
  25. Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage. 2008;16(5):615-623. doi:10.1016/j.joca.2007.09.006.
  26. Hayes CW, Jamadar DA, Welch GW, et al. Osteoarthritis of the knee: comparison of MR imaging findings with radiographic severity measurements and pain in middle-aged women. Radiology. 2005;237(3):998-1007. doi:10.1148/radiol.2373041989.
  27. Ishijima M, Watari T, Naito K, et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011;13(1):R22. Published 2011 Feb 14. doi:10.1186/ar3246.
  28. Hyun JK, Tae SJ, Wan SK, Young SP. Comparison of Histological Changes in Accordance with the Level of Dextrose-Concentration in Experimental Prolotherapy Model. Ann Rehabil Med [Internet]. 2003;(27)6. p935–940. Available from:
  29. Jensen KT, Rabago DP, Best TM, Patterson JJ, Vanderby R Jr. Response of knee ligaments to prolotherapy in a rat injury model. Am J Sports Med. 2008;36(7):1347-1357. doi:10.1177/0363546508314431.
  30. Soliman D. Pain Management by Prolotherapy and Perineural Injection Therapy. LAP Lambert Academic Publishing. 2016. p21.
  31. Klocke R, Levasseur K, Kitas GD, Smith JP, Hirsch G. Cartilage turnover and intra-articular corticosteroid injections in knee osteoarthritis. Rheumatol Int. 2018;38(3):455-459. doi:10.1007/s00296-018-3988-2.
  32. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60(6):619-626. doi:10.1136/ard.60.6.619.
  33. Bihlet AR, Byrjalsen I, Bay-Jensen AC, et al. Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis. Arthritis Res Ther. 2019;21(1):203. Published 2019 Sep 3. doi:10.1186/s13075-019-1987-7.
  34. Bay-Jensen AC, Tabassi NC, Sondergaard LV, et al. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther. 2009;11(1):R9. doi:10.1186/ar2596.
  35. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365(9463):965-973. doi:10.1016/S0140-6736(05)71086-2.
  36. Cahue S, Sharma L, Dunlop D, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 2007;15(7):819-823. doi:10.1016/j.joca.2007.01.016.
  37. Cibere J, Zhang H, Garnero P, et al. association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009;60(5):1372-1380. doi:10.1002/art.24473.
  38. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002;46(10):2613-2624. doi:10.1002/art.10576.
  39. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol. 2005;17(5):624-628. doi:10.1097/01.bor.0000172800.49120.97.
  40. Creamer P. Osteoarthritis pain and its treatment. Curr Opin Rheumatol. 2000;12(5):450-455. doi:10.1097/00002281-200009000-00019.

How to Cite

Waluyo, Y., Agussalim Bukhari, Endy Adnan, Artika, S. R., Ahmad Yasin, Insani Nanda Wahyuni, & Budu. (2022). Association between cartilage biomarker level and functional outcome in knee osteoarthritis patients receiving dextrose prolotherapy: a cross-sectional study. Bali Medical Journal, 11(3), 1151–1156.